Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 9/20 | 0.43 |
| ▸ | MAOB | P27338 | 9/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5740932 | 0.82 | AHR (0.55) | MAOAMAOBHTR7CA9 | |
| SCHEMBL29754281 | 0.77 | CA9 (0.62) | MAOAMAOBKMT2AKDM4ELMNA | |
| SCHEMBL4102521 | 0.77 | CA9 (0.62) | MAOAMAOBKMT2AKDM4ELMNA | |
| SCHEMBL7505614 | 0.76 | MAPT (0.59) | KMT2AKDM4ELMNASMN1; SMN2CA9 | |
| SCHEMBL2625799 | 0.76 | MAOA (0.55) | MAOAMAOBHTR7 | |
| SCHEMBL5739472 | 0.75 | PARP1 (0.39) | DPP4MAOAMAOB | |
| SCHEMBL1903261 | 0.75 | DRD1 (0.50) | MAOAMAOB | |
| SCHEMBL12363785 | 0.74 | MAOA (0.59) | MAOAMAOBHTR7 | |
| SCHEMBL27554931 | 0.73 | BRD4 (0.59) | — | |
| SCHEMBL260027 | 0.72 | AHR (0.61) | MAOBKMT2AKDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497296-B1 | [1,4]DIAZOCINO[7,8,1-hi]INDOLE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS | WYETH CORP (US) | 2006-03-22 | — | — | EP | disclosed |
| US-7012089-B2 | [1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents | WYETH (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040034005-A1 | [1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents | WYETH | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034005-A1 | [1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents | HTR1A, HTR2C, HTR1D | NR3C2 449/4885DPP4 419/4885MAOA 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.